Astellas Pharma (OTCMKTS:ALPMY) Stock Passes Below Fifty Day Moving Average – Time to Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $11.14 and traded as low as $10.03. Astellas Pharma shares last traded at $10.44, with a volume of 139,754 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALPMY. Sanford C. Bernstein cut shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy”.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.38, a current ratio of 1.17 and a quick ratio of 0.89. The business’s 50 day moving average is $11.14 and its 200 day moving average is $10.15.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.26. Astellas Pharma had a return on equity of 19.67% and a net margin of 4.34%.The business had revenue of $3.41 billion during the quarter, compared to analyst estimates of $3.20 billion. Equities analysts forecast that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.